Zheng Quan Ri Bao·2025-08-21 08:35Core Insights - Nocera Healthcare reported a 74.3% year-on-year revenue growth in the first half of 2025, reaching 730 million yuan, driven by the strong performance of its core product, Oubatinib (brand name: Yinuokai®), and an upfront payment from a licensing agreement with Prolium [2][3] - The company's drug revenue increased by 53.5% year-on-year to 640 million yuan, primarily due to Oubatinib's inclusion in the national medical insurance, which has expanded its patient base, particularly in the marginal zone lymphoma indication [2] - Nocera's losses decreased by 86.7% year-on-year to 36 million yuan, attributed to increased operating income and improved cost efficiency [2] Financial Performance - Research and development expenses rose by 6.9% year-on-year to 450 million yuan, mainly for building a differentiated R&D platform and advancing more Phase III clinical projects [2] - As of June 30, 2025, the company held approximately 7.68 billion yuan in cash and cash equivalents, which will support the acceleration of multiple Phase III registration clinical trials and investments in differentiated ADC and other pipelines [2] Strategic Developments - 2025 marks the 10th anniversary of the company, which is entering a new phase of rapid development [3] - Significant progress has been made in advancing the product pipeline, achieving multiple key milestones that lay a solid foundation for long-term growth [3] - The company has formed strategic partnerships to expand its global footprint, including a licensing collaboration with Connoa and Prolium Bioscience to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355) [3] - Nocera continues to enhance its commercialization team's capabilities, leading to increased market penetration and revenue growth for Oubatinib, demonstrating the company's ability to translate scientific innovation into sustained business performance [3]